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Abstract
Objectives:  To  evaluate  the  prevalence  and  circulation  of  rotavirus  genotypes  before  and  after
the introduction  of  oral  vaccine  against  human  rotavirus,  and  to  check  for  a  possible  change  in
the  age  of  occurence  of  the  infection  by  RV-A.
Methods:  This  was  a  cross-sectional  study  conducted  between  2002-2011,  in  the  city  of  Juiz  de
Fora,  state  of  Minas  Gerais,  Brazil.  A  total  of  1,144  diarrheal  stool  specimens  were  obtained
from  nonhospitalized  children  aged  between  0  and  5  years,  and  analyzed  by  polyacrylamide  gel
electrophoresis  and  reverse-transcription  polymerase  chain  reaction  for  genotype  characteri-
zation.  Data  on  prevalence  and  age  distribution  of  rotavirus  cases  were  analyzed  through  the
chi-squared  test  (p  <  0.05),  using  SPSS,  release  13.0.
Results:  Rotavirus  infection  was  detected  in  9.35%  (107/1,144)  samples,  with  prevalence  rates
ranging from  11.12%  (90/809)  in  the  pre-vaccine  to  5.07%  (17/335)  in  the  post-vaccine  period
(p  =  0.001).  Among  the  samples  tested,  the  most  frequently  detected  genotypes  were  G1P[6]
(6/33  =  18.2%)  in  the  period  between  2002  and  2005  and  G2P[4]  in  2006  (11/33  =  33.3%)  and
in  the  period  between  2007  and  2011  (5/33  =  15.2%).  There  was  also  a  signiﬁcant  reduction  in
the  number  of  cases  of  rotavirus  disease  in  children  aged  between  0  and  36  months  after  the
vaccine  introduction.
 Please cite this article as: Assis AS, Valle DA, Antunes GR, Tibiric¸a  SH, Assis RM, Leite JP, et al. Rotavirus epidemiology before and after
accine introduction. J Pediatr (Rio J). 2013;89:470--6.
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Conclusions:  The  study  evidenced  a  signiﬁcant  decrease  in  the  prevalence  of  rotavirus,  mainly
in children  aged  between  0  and  36  months  in  the  2007-2011  period,  as  well  as  a  reduction  in
G1  genotype  circulation.
© 2013  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Epidemiologia  das  rotaviroses  antes  e  após  a  introduc¸ão  da  vacina
Resumo
Objetivos:  Avaliar  a  prevalência  e  a  circulac¸ão  dos  genótipos  de  rotavírus,  antes  e  após  a
introduc¸ão da  vacina  oral  contra  rotavírus  humano,  bem  como  veriﬁcar  uma  possível  mudanc¸a
na faixa  etária  de  ocorrência  da  infecc¸ão  pelo  RV-A.
Métodos:  Trata-se  de  um  estudo  transversal  realizado  no  período  de  2002  a  2011,  em  Juiz
de Fora,  MG.  Foram  avaliados  1.144  espécimes  fecais  diarreicos,  obtidos  de  crianc¸as  de  0  a
cinco  anos  não  hospitalizadas,  que  foram  analisadas  por  PAGE  e  RT-PCR.  Os  dados  relativos  à
prevalência  e  distribuic¸ão  etária  dos  casos  de  rotavirose  foram  analisados  pelo  teste  2 (p  <
0,05),  utilizando-se  o  programa  SPSS,  versão  13.0.
Resultados:  Infecc¸ões  por  rotavírus  foram  detectadas  em  9,35%  (107/1.144)  das  amostras,  com
prevalências variando  de  11,12%  (90/809)  no  período  pré-vacinal  a  5,07%  (17/335)  no  pós-vacinal
(p  =  0,001).  Dentre  as  amostras  caracterizadas,  os  genótipos  mais  frequentemente  detectados
foram  G1P[6]  (6/33  =  18,2%)  no  período  2002-2005  e  G2P[4]  no  ano  de  2006  (11/33  =  33,3%)  e
no  período  2007-2011  (5/33  =  15,2%).  Observou-se,  ainda,  uma  reduc¸ão  signiﬁcativa  no  número
de  casos  de  rotavirose  em  crianc¸as  de  0  a  36  meses,  após  a  introduc¸ão  da  vacina.
Conclusões: O  estudo  revelou  queda  signiﬁcativa  na  prevalência  de  rotavírus,  principalmente
na faixa  etária  de  0  a  36  meses,  no  período  2007-2011,  bem  como  reduc¸ão  na  circulac¸ão  do
genótipo  G1.
© 2013  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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Group  A  rotaviruses  (RV-A)  are  important  viral  pathogens
associated with  acute  diarrheal  disease  (ADD)  in  children.
Around the  world,  they  are  responsible  for  125  million
episodes of  diarrhea,  25  million  physician  consultations,  2.4
million  hospitalizations,  and  611,000  deaths  per  year;  29%  of
all diarrhea  deaths  involve  children  younger  than  5  years.1,2
In  developing  countries,  RV-A  are  directly  related  to  child
mortality and  high  morbidity,  considering  the  large  number
of hospitalizations  by  diarrhea  and  dehydration,  impacting
the family,  society,  public  health  care  expenses,  productiv-
ity, and  psychosocial  and  environmental  aspects.1 In  Latin
America, according  to  available  data  were  recorded  ten
million cases  of  diarrhea,  two  million  doctor  consultations,
75,000 hospitalizations,  and  15,000  deaths  annually  caused
by RV-A.3
In  Brazil,  before  vaccination,  RV-A  were  associated  with
3.5 million  episodes  of  ADD,  650,000  outpatient  visits  to
health care  facilities,  92,000  hospitalizations,  and  850
deaths per  year  in  children  aged  <  5  years.4 Studies  per-
formed in  the  secondary  and  tertiary  levels  of  health  care
with individuals  of  the  same  age  group  demonstrated  that
the prevalence  of  diarrhea  disease  by  RV-A  ranged  from
20.7% to  30.9%,5 and  this  virus  was  also  considered  an  impor-
tant cause  of  hospitalization.RV-A infection  is  self-limited  and  can  be  symptomatic
or asymptomatic.  The  clinical  picture  of  the  disease  varies
from mild  to  severe  and  can  lead  to  dehydration.  It  affects
individuals in  all  age  groups,  but  predominantly  infants.6
i
R
sRV-A  belong  to  the  genus  Rotavirus,  family  Reoviridae,
hose genome  consists  of  11  segments  of  double-stranded
NA. Genotypes  are  classiﬁed  according  to  a  binary  system
hrough the  determination  of  gene  sequences  that  encode
he VP7  (G  types)  and  VP4  (P  types)  proteins.6 However,  a
ore complete  classiﬁcation  system  was  recently  suggested,
ased on  the  sequence  of  all  genomic  segments  of  the  virus.7
he  most  common  G  and  P  combinations  worldwide  are:
1P[8], G2P[4],  and  G9P[8].5
Improved  sanitation  and  hygiene  habits  are  desirable  for
he prevention  of  diarrheal  diseases,  but  not  enough  to  pre-
ent infection  by  RV-A.  Thus,  studies  have  focused  on  the
evelopment of  a  vaccine,  aiming  to  reduce  the  number  of
evere cases  of  the  disease  and  consequent  hospitalizations
nd deaths  in  all  socioeconomic  levels.  In  the  last  decade,
everal candidates  were  tested  without  success  until  devel-
pment of  Rotarix  monovalent  vaccine®  (GlaxoSmithKline
- Rixensart,  Belgium)  produced  using  an  human-attenuated
V-A G1P[8].1
The  Rotarix  vaccine®  was  introduced  in  the  National
mmunization Program  of  Brazil  in  March  of  2006,8 and  was
lso implemented  in  other  11  Latin  American  countries.5
lthough  the  immunity  conferred  by  the  vaccine  protects
gainst severe  disease,  reinfections  by  different  genotypes
f RV-A  can  occur  throughout  life,  as  these  viruses  have  a
igh genetic  diversity.9In  this  context,  genotypic  characterization  studies  are
mportant to  understand  the  impact  of  vaccination  on  the
V-A genotypes  circulating  in  the  population  and  to  provide
ubsidies for  reassessment  of  the  formulations  in  the  search
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iigure  1  Annual  prevalence  of  RV-A  in  the  period  2002-2011  
D, no  data  available.17
or  a  more  appropriate  vaccine.  Thus,  the  objective  of  this
tudy was  to  evaluate  the  prevalence  of  RV-A  infection  and
irculation of  RV-A  genotypes  before  and  after  the  introduc-
ion of  oral  vaccine  against  human  rotavirus,  as  well  as  to
heck for  a  possible  change  in  the  age  of  occurence  of  the
nfection by  RV-A.
ethods
his  was  cross-sectional  study  that  analyzed  1,144  fecal
amples from  non-hospitalized  children  aged  0-5  years,  with
linical evidence  of  ADD,  attended  at  public  outpatient  clin-
cs and  private  ofﬁces,  from  2002  to  2011  in  the  city  of  Juiz
e Fora,  state  of  Minas  Gerais,  Brazil.
This  study  was  approved  by  the  Ethics  Committee  on
uman Research  of  the  Universidade  Federal  de  Juiz  de
ora. Fecal  samples  were  kept  under  refrigeration  (4 ◦C)  and
ent to  the  virology  laboratory,  where,  after  registration,
hey were  stored  at  -20 ◦C,  constituting  a  bank  of  samples
t the  Universidade  Federal  de  Juiz  de  Fora.
Fecal  suspensions  (10%  w/v)  were  prepared  in  Tris-HCl-
a+2 buffer,  at  pH  7.2,  clariﬁed  (5,000  rpm  for  20  minutes  at
◦C)  and  submitted  to  RNA  extraction  technique,10 followed
y polyacrylamide  gel  electrophoresis  (PAGE)11 metodology
or RV-A  detection.
The genotypic  characterization  of  positive  RV-A  samples
as performed  by  polymerase  chain  reaction  preceded  by
everse transcription  (RT-PCR),  using  consensus  primers  for
he ampliﬁcation  of  genes  encoding  the  VP7  and  VP4  pro-
eins, followed  by  multiplex  seminested  PCR  with  speciﬁc
ucleotide primers  for  the  main  genotypes  G  (G1,  G2,  G3,
4, G8,  and  G9)12,13 and  P  P[4],  P[6],  P[8]  e  P[9]14 of  human
V-A.
i
l
6accine  coverage.
Data  on  the  prevalence  and  age  distribution  of  positive
V-A samples  were  entered  in  the  Statistical  Package  for
ocial Sciences  (SPSS),  release  13.0.  Comparison  of  the  rate
f RV-A  detection  and  age  groups  during  the  study  period
as performed  by  the  chi-squared  test,  considering  p-values
 0.05  as  statistically  signiﬁcant.
esults
o  assess  the  possible  inﬂuence  of  vaccination  on  the  preva-
ence of  rotavirus  and  the  age  group  affected  by  the  disease,
he study  period  was  divided  into  pre-vaccine  (2002-2006)
nd post-vaccine  (2007-2011).  Although  2006  was  the  year
hen the  vaccine  was  introduced,  it  was  included  in  the  pre-
accination period  (2002-2006),  as  the  majority  (187/194  =
6.39%) of  the  samples  were  obtained  from  children  who
ere not  eligible  for  vaccination.  However,  for  the  analy-
is of  circulating  genotypes,  considering  that  other  factors,
n addition  to  vaccination,  could  have  an  impact  on  this
ynamic, the  study  period  was  divided  into  2002-2005,  2006,
nd 2007-2011.
In this  study  was  observed  a positivity  rate  of  9.35%
107/1,144), with  a  prevalence  of  ADD  associated  with  RV-
 ranging  from  11.12%  (90/809)  in  the  period  before  the
ntroduction of  the  vaccine  to  5.07%  (17/335),  in  the  period
fter its  implementation,  which  was  statistically  conﬁrmed
p = 0.001).
The annual  prevalence  of  RV-A  and  the  comparison  with
he vaccination  coverage  achieved  in  the  period  are  exhib-
ted in  Fig.  1,  where  the  curve  shows  a  sharp  decline  in  the
ncidence of  rotavirus  disease  in  2007.
Of  the  70  positive  RV-A  samples  submitted  to  molecu-
ar characterization,  52  (74.3%)  were  genotyped.  Of  these,
3.5% (33/52)  were  completely  characterized,  and  a  total
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Table  1  Complete  genotypic  characterization  of  RV-A  samples,  in  the  period  2002-2011.
Genotypes  Analyzed  period  Prevalence  (positive/total)
Pre-vaccine  Post-vaccine
2002-2005  2006  2007-2011
G1P[4]  -  -  01  3.0%  (1/33)
G1P[6]  06  -  -  18.2%  (6/33)
G1P[8]  02  -  -  6.1%  (2/33)
G2P[4]  -  11  05  48.5%  (16/33)
G2P[6]  -  02  -  6.1%  (2/33)
G2P[8]  -  01  -  3.0%  (1/33)
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of  seven  combinations  of  G  and  P  genotypes  (Table  1)  were
identiﬁed, highlighting  G1P[6]  in  the  period  between  2002
and 2005  and  G2P[4]  from  the  year  2006  onward.  Conversely,
36.5% of  the  samples  (19/52)  were  partially  characterized,
highlighting the  genotypes  G1  (7/19  =  36.8%)  in  2002-2005
and P[4]  (4/19  = 21.1%)  in  2006.  Even  after  several  attempts,
it was  not  possible  to  characterize  25.7%  (18/70)  of  the  sam-
ples, most  of  them  obtained  in  the  period  between  2007  and
2011.
The characterization  of  the  RV-A  samples  evidenced  the
predominance of  the  G1  genotype  in  2002-2005,  with  a
signiﬁcant decline  in  the  2007-2011  period;  however,  no
samples of  this  genotype  were  detected  in  the  year  of
vaccine introduction  (2006).  G2  samples,  which  were  not
detected in  the  2002-2005  period,  prevailed  from  2006
onwards, while  G9  samples  were  detected  only  in  the  2002-
2005 period  (Fig.  2).Regarding  the  P  genotype,  Fig.  2  shows  that  the  P[8]
and P[4]  types  were  detected  throughout  the  study  period;
P [8]  was  the  predominant  type  in  the  2002-2005  period.  The
P[4] type,  however,  was  seldom  detected  in  2002-2005,  but
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Figure  2  Partial  genotypic  characterization  of  RV-A  samples,  in  th
NI, not  identiﬁed.-  15.1%  (5/33)
revailed  in  the  year  of  vaccine  introduction  (2006),  show-
ng smaller  proportions  in  the  2007-2011  period.  The  P[6]
ype was  detected  only  in  the  2002-2005  period  (Fig.  2).
The  analysis  of  distribution  of  positive  RV-A  samples,
ccording to  age,  in  the  pre-  and  post-vaccination  periods
Table 2)  demonstrated  a  signiﬁcant  reduction  in  the  num-
er of  cases  of  rotavirus  disease  in  children  aged  between  0
nd 36  months  in  the  post-vaccination  period.  Although  all
ecal samples  were  collected  from  children  aged  between
 and  5  years  in  2002  (19/318)  and  2003  (12/164),  there
as no  accurate  information  on  age.  So  these  samples  were
herefore not  included  in  Table  2.
iscussion
he  introduction  of  vaccine  in  the  National  Immunization
rogram was  a  breakthrough,  and  can  be  an  effective  mea-
ure to  decrease  the  incidence  of  severe  rotavirus  disease
nd infant  mortality.15 However,  in  order  to  assess  the
mpact of  the  measure  on  the  disease  occurrence  and  the
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e  period  2002-2011.
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Table  2  Age  range  distribution  of  positive  samples  for  RV-A,  in  the  2004-2011  period.
Age  range  (months)  Positivity  (positive/tested)  p-value
Pre-vaccine  (2004-2006) Post-vaccine  (2007-2011)
0--12  9.3%  (10/107)  1.8%  (02/111)  0.016
13--24 30.8%  (20/65) 4.8%  (06/124) 0.000
25--36 22.4%  (11/49) 4.8%  (02/42) 0.018
37--48 26.7%  (08/30) 10.5%  (02/19) 0.278
49--60 12.9%  (04/31)  16.1%  (05/31)  1.000
UA  13.3%  (06/45)  0.0%  (00/05)  0.360
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uctuations  of  different  RV-A  genotypes,  it  is  necessary
o perform  continuous  longitudinal  epidemiological  surveil-
ance after  the  vaccine  introduction.
Vaccination  was  started  in  2006,  reaching  only  56.48%  of
he target  population  in  the  city.  In  addition  to  low  immu-
ization coverage,  it  is  relevant  to  observe  that,  in  this
tudy, the  majority  of  samples  were  obtained  from  children
ho were  outside  the  age  group  considered  eligible  for  vac-
ination, which  partly  explains  the  fact  that  the  prevalence
f RV-A  was  similar  to  that  observed  in  2005.
In  2007,  however,  there  was  a  signiﬁcant  decrease  in
he rate  of  virus  detection,  corroborating  data  from  other
esearchers in  Brazil  in  the  same  year.  This  decrease  was
oncomitant with  an  increase  in  the  vaccination  coverage  in
he municipality,  which  reached  80.47%  of  eligible  children
uring that  year.16--18
The  comparative  analysis  between  the  pre-  and  post-
accination periods  demonstrated  a  signiﬁcant  reduction
n the  prevalence  of  RV-A  in  2007-2011.  This  ﬁnding  cor-
oborates other  Brazilian  studies,  which  reported  a  similar
rend17--19 even  in  the  hospital  environment,  where  vaccina-
ion was  associated  with  an  overall  reduction  in  the  number
f consultations  and  hospitalizations  by  ADD.20 This  reduc-
ion in  the  occurrence  of  the  disease  caused  by  RV-A  is
mportant, as  it  implies  reduction  of  comorbidities  and  of
he ﬁnancial  burden  to  the  Brazilian  health  system.
Despite  the  observed  reduction,  a  trend  of  gradual
ncrease in  the  prevalence  of  RV-A  was  observed  the  period
f 2008-2011,  even  considering  the  smaller  number  of  sam-
les obtained  during  these  years  of  study.  Partially  similar
ata were  reported  in  a  study  conducted  in  the  Triân-
ulo Mineiro  area,  Western  Minas  Gerais,  where  the  largest
ecrease in  the  prevalence  of  RV-A  was  observed  in  2009,  but
ith  an  upward  trend  in  2010,  in  the  city  of  Uberlândia.21
Before  the  introduction  of  vaccine  (2002-2005),  RV-A
1P[8] were  predominant  in  Brazil.5 In  this  same  period,  in
he city  of  Juiz  de  Fora,  the  largest  circulation  of  G1  samples
as also  observed;  however,  with  a  predominance  of  G1P[6]
ollowed by  G9P[8]  and  G1P[8].  Molecular  characterization
f the  samples  detected  in  2006  showed  a  predominance  of
2P[4] reinforcing  reports  of  studies  carried  out  in  different
tates of  Brazil  and  other  countries.17,22--24 In  the  year  when
he G1P[8]  vaccine  was  implemented  in  the  Brazilian  Uni-
ed Health  System  (Sistema  Único  de  Saúde  -  SUS),  a  high
revalence of  RV-A  was  observed,  associated  with  low  vac-
ination coverage  and  greater  circulation  of  G2  genotype
amples. Seldom  detected  in  the  country  since  1996,  such
c
a
i
bamples  re-emerged  in  2006,  thus  conﬁrming  the  observa-
ion that  they  have  a characteristic  circulation  that  occurs
t ten-year  intervals.22
RV-A  G2P[4]  samples  may  have  been  reintroduced  into
razil in  2005,  through  states  bordering  other  countries  in
outh America  that  reported  the  disease  associated  with
2 genotype25 and  others  that  have  not  implemented  the
accination.24 The  long  period  of  little  or  no  circulation
f this  genotype  would  have  created  favorable  condi-
ions for  the  accumulation  of  immunologically  susceptible
ndividuals,26 which  may  explain  the  high  prevalence  of
nfection, even  with  the  use  of  vaccine.
Studies  of  cross-reactivity  of  vaccine  performed  in  Latin
merica evidenced  heterotypic  response  only  against  G3,
4, and  G9  samples.15 However,  the  evaluation  of  the
esponse against  G2  samples  may  have  been  impaired  by
he low  circulation  of  this  genotype  during  the  screening
tudies.15 Recent  studies20,27 supported  this  theory,  showing
vidence of  vaccine  efﬁcacy  against  the  G2P[4]  genotype,
specially in  children  aged  between  six  and  11  months,  with
eclining protection  after  12  months  of  age.
Since  2007,  the  prevalence  of  infection  has  decreased.  G2
amples remained  predominant,  cocirculating  mainly  with
1 samples,  both  at  a  lesser  extent  than  in  2006  and  2005,
espectively, according  to  reports  by  other  authors.24 During
his period,  in  addition  to  the  anti-G1  homotypic  protection
nd heterotypic  protection  against  other  genotypes  con-
erred by  the  vaccine,  the  number  of  individuals  already
ensitized against  G2  genotype,  who  have  accumulated  in
he population,  should  be  considered.17,22,24
Thus,  the  reemergence  of  G2  samples  can  be  attributed
oth to  characteristic  ﬂuctuations  of  this  genotype,  as  well
s to  a  possible  selective  advantage  granted  by  the  vaccine.
owever, the  ﬁnding  that  G2  samples  were  prevalent  in  this
eriod, even  in  countries  where  vaccine  had  not  yet  been
mplemented,23,25,28 reinforces  the  theory  of  temporal  ﬂuc-
uation. Therefore,  from  the  perspective  of  epidemiological
urveillance, it  is  essential  to  maintain  sequential  studies  to
valuate the  genotypic  variations  of  RV-A.
It  was  not  possible  to  characterize  a  percentage  of  the
ositive samples,  despite  several  attempts  at  genotyping;
ost of  them  were  detected  in  the  2007-2011  period.  This
ifﬁculty has  been  previously  observed,18 and  can  be  asso-
iated with  the  presence  of  inhibitors  in  fecal  specimens
nd/or the  involvement  of  different  genotypes  of  RV-A  not
ncluded in  the  PCR  reaction,  selected  by  pressure  of  anti-
odies elicited  by  the  vaccine.
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2Rotavirus  epidemiology  before  and  after  vaccine  introductio
Studies  on  the  post-vaccine  period  have  focused  on  the
veriﬁcation of  the  inﬂuence  of  vaccination  on  the  prevalence
of infection  and  characterization  of  circulating  genotypes,
with few  reports  on  a  possible  change  in  the  age-range
of higher  occurrence  of  infection.  In  this  context,  this
study demonstrated  that  in  the  pre-vaccine  period,  rotavirus
infection was  observed  in  children  aged  0  to  60  months,
especially in  the  age  group  between  13  and  24  months.
Conversely, in  the  post-vaccine  period,  there  was  a  signiﬁ-
cant reduction  in  the  rate  of  positivity  in  children  aged  0  to
36 months,  even  considering  the  loss  of  data  for  the  years
2002 and  2003.  Similar  results  have  also  been  observed  in
hospitalized children,  showing  a  signiﬁcant  reduction  in  hos-
pitalization for  diarrheal  disease  associated  with  RV-A,  in  the
age group  of  0  to  23  months.29 Taken  together,  these  results
suggest that  vaccination  considerably  inﬂuenced  reduction
in infection  and  severe  disease  by  RV-A  in  the  age  group  of
0 to12  months,  which  was  previously  considered  the  most
vulnerable group.  In  this  respect,  it  must  also  be  consid-
ered that  this  decrease  includes  herd  immunity  induced  by
mass vaccination  against  RV-A  in  unvaccinated  children,  as
recently reported  by  other  authors.30
This  study  demonstrated  a  signiﬁcant  decrease  in  the
prevalence of  RV-A  in  the  period  2007-2011,  especially  in
the age  group  between  0  and  36  months,  and  a  decrease
in the  circulation  of  non-G2  genotypes,  predominant  during
the 2002-2005  period  in  the  municipality,  after  the  imple-
mentation of  vaccine.
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